Very interesting journal letter that our friends at CML Advocates Network shared today.
It is short on data, but suggests that from what is known patients in chronic phase CML taking TKIs are not at higher risk of contracting COVID-19 than the general population. This may not be the case for a CML patient with other underlying health issues.
It suggests that drug-drug interactions between TKIs and other drugs used to treat COVID-19 could be somewhat problematic.
It concludes that CML patients should continue receiving their TKIs, if they have COVID-19 disease, but drug-drug interactions should always be taken into consideration in certain circumstances.
The journal letter is scientifically written, but should be readable by most seasoned CML patients.